Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Shigella4V Vaccine in Adults, Children, and Infants
NCT04056117Phase 2Completed
- Sponsor
- LimmaTech Biologics
- Start
- Sep 2019
- Primary completion
- Sep 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of Shigella4V in shigellosis, sponsored by LimmaTech Biologics. Started Sep 2019; status: completed.
02
Drugs
Shigella4V
03
Conditions
shigellosis
Beyond the preview
Go deeper on NCT04056117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04056117.